Business
SELLAS Life Sciences Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based Regimens Patients – – SLS009 Shows Promising Efficacy in Pediatric Acute Lymphoblastic Leukemia (ALL) Xenograft Models – – Final Analysis of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Anticipated in 2025 – – $28.4 million in Cash and Cash Equiva
About this update from Sellas Life Sciences Group, Inc.
[{"type":"image","alt":"SELLAS Life Sciences Group, Inc.","displaySize":"","headline":null,"caption":"SELLAS Life Sciences Group, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":99,"url":"https://media.zenfs.com/en/globenewswire.com/1570633a12e0dc941a3e2343b15473ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GShh9i.pLECdgZkEWUY8Tg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1570633a12e0dc941a3e2343b15473ec","width":300,"height":99}},"lazy":false},{"type":"text","content":"– Announced Positive Overall Survival in Cohort 3 from the Ongoing Phase 2 Trial of SLS009 (tambiciclib) in Relapsed/Refractory (r/r) Acute Myeloid Leukemia (AML) Demonstrating 8.9 mOS in AML-MRC and 8.8 mOS in All r/r to Venetoclax-Based Regimens Patients –","length":258,"tagName":"p"},{"type":"text","content":"– SLS009 Shows Promising Efficacy in Pediatric Acute Lymphoblastic Leukemia (ALL) Xenograft Models –","length":105,"tagName":"p"},{"type":"text","content":"– Final Analysis of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in AML Anticipated in 2025 –","length":100,"tagName":"p"},{"type":"text","content":"– $28.4 million in Cash and Cash Equivalents as of March 31, 2025; Additional $4.0 million Proceeds received in April 2025 through Warrant Exercises –","length":155,"tagName":"p"},{"type":"text","content":"NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.","length":363,"tagName":"p"},{"type":"text","content":"“We are very encouraged by the strong momentum across our pipeline,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. “The positive overall survival data in cohort 3 from the ongoing Phase 2 trial of SLS009 in r/r AML, showing a median OS that exceeds all historical benchmarks by over 3 times, further underscores the transformative potential of SLS009 for many underserved patients. In parallel, our new preclinical findings demonstrating the ability of SLS009 to overcome TP53-driven resistance, along with the prom...